Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID‐19
B Damle, M Vourvahis, E Wang… - Clinical …, 2020 - Wiley Online Library
Azithromycin (AZ) is a broad‐spectrum macrolide antibiotic with a long half‐life and a large
volume of distribution. It is primarily used for the treatment of respiratory, enteric, and …
volume of distribution. It is primarily used for the treatment of respiratory, enteric, and …
[HTML][HTML] Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug–drug interaction studies
M Elmeliegy, M Vourvahis, C Guo, DD Wang - Clinical pharmacokinetics, 2020 - Springer
Understanding transporter-mediated drug–drug interactions (DDIs) for investigational agents
is important during drug development to assess DDI liability, its clinical relevance, and to …
is important during drug development to assess DDI liability, its clinical relevance, and to …
Maraviroc: pharmacokinetics and drug interactions
S Abel, DJ Back, M Vourvahis - Antiviral therapy, 2009 - journals.sagepub.com
Maraviroc is a potent selective CCR5 antagonist and is the first of this new class of oral
agents to be approved for the treatment of CCR5-tropic HIV type-1. Maraviroc is extensively …
agents to be approved for the treatment of CCR5-tropic HIV type-1. Maraviroc is extensively …
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity
SJ Schrieber, Z Wen, M Vourvahis, PC Smith… - Drug Metabolism and …, 2008 - ASPET
Silymarin, used by 30 to 40% of liver disease patients, is composed of six major flavonolignans,
each of which may contribute to silymarin's hepatoprotective properties. Previous studies …
each of which may contribute to silymarin's hepatoprotective properties. Previous studies …
Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs
…, E Kimoto, S Yamazaki, M Vourvahis… - Clinical …, 2023 - Wiley Online Library
Hepatic impairment (HI) is known to modulate drug disposition and may lead to elevated
plasma exposure. The aim of this study was to quantitate the in vivo OATP1B‐mediated hepatic …
plasma exposure. The aim of this study was to quantitate the in vivo OATP1B‐mediated hepatic …
Dose‐dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs
…, JG Johnson, VH Le, M Vourvahis… - Clinical …, 2020 - Wiley Online Library
To address the most appropriate endogenous biomarker for drug–drug interaction risk
assessment, eight healthy subjects received an organic anion transporting polypeptide 1B (…
assessment, eight healthy subjects received an organic anion transporting polypeptide 1B (…
A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir
JB Dumond, M Vourvahis, NL Rezk… - Clinical …, 2010 - Wiley Online Library
The effects of tipranavir/ritonavir (TPV/r) on hepatic and intestinal P‐glycoprotein (P‐gp) and
cytochrome P450 (CYP) enzyme activity were evaluated in 23 volunteers. The subjects …
cytochrome P450 (CYP) enzyme activity were evaluated in 23 volunteers. The subjects …
Biomarker‐informed model‐based risk assessment of organic anion transporting polypeptide 1B mediated drug‐drug interactions
…, MA West, Y Bi, M Vourvahis… - Clinical …, 2022 - Wiley Online Library
… (0.3 µM) > 10-fold below its K m values (3.8 and 28 µM for OATP1B1 and OATP1B3, … ,OATP1B,
measured using rosuvastatin as probe drug at concentration below its K m (ie, K i …
measured using rosuvastatin as probe drug at concentration below its K m (ie, K i …
[HTML][HTML] Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients
…, A Petrie, A Riskalla, Z Hamdoon, M Vourvachis… - Head & neck …, 2010 - Springer
The incidence of oral squamous cell carcinoma remains high. Oral and oro-pharyngeal
carcinomas are the sixth most common cancer in the world. Several clinicopathological …
carcinomas are the sixth most common cancer in the world. Several clinicopathological …
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis …
Introduction Small molecule inhibitors of the terminal step in intrahepatic triglyceride
synthesis (diacylglycerol acyltransferase 2 inhibitor (DGAT2i, PF-06865571, ervogastat)) and …
synthesis (diacylglycerol acyltransferase 2 inhibitor (DGAT2i, PF-06865571, ervogastat)) and …